Suppr超能文献

SIRT1-ZEB1 正反馈促进骨肉瘤上皮-间充质转化过程和转移。

SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.

机构信息

Division of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

J Cell Biochem. 2019 Mar;120(3):3727-3735. doi: 10.1002/jcb.27653. Epub 2018 Oct 10.

Abstract

Osteosarcoma is the most common malignant bone cancer that mainly affects children and young adults. Recently, the NAD -dependent deacetylase, sirtuin 1 (SIRT1), has been reported to play a key role in the development of malignant tumors. The study aimed to investigate the role of SIRT1 in osteosarcoma and explore its underlying oncogenic mechanisms. The prognostic value of SIRT1 in osteosarcoma was assessed through detection of SIRT1 expression based on osteosarcoma biopsy tissue. Then, to further investigate the effect of SIRT1 in osteosarcoma, osteosarcoma cells were treated with small interfering RNA SIRT1 and overexpressed SIRT1 to detect the cell migration, invasion, and epithelial-mesenchymal transition (EMT). The levels of SIRT1 expression were significantly higher in osteosarcoma tissues than those in adjacent normal tissues, and the SIRT1 protein level may be coupled with metastatic and poor prognosis risk in patients with osteosarcoma. Moreover, SIRT1 silencing inhibited the migration as well as invasion ability of osteosarcoma cells in vitro, and SIRT1 upregulation reversed those effects. Finally, we found that SIRT1-ZEB1-positive feedback enhanced the EMT process and metastasis of osteosarcoma. Altogether, the results of the current study revealed that high levels of SIRT1 might be a biomarker for a high metastatic rate in patients with osteosarcoma, which suggested that inhibition of SIRT1 might be promising for the therapeutics of osteosarcoma.

摘要

骨肉瘤是最常见的恶性骨癌,主要影响儿童和青少年。最近,NAD 依赖性去乙酰化酶,沉默调节蛋白 1(SIRT1),被报道在恶性肿瘤的发展中发挥关键作用。本研究旨在探讨 SIRT1 在骨肉瘤中的作用及其潜在的致癌机制。通过检测骨肉瘤活检组织中 SIRT1 的表达来评估 SIRT1 在骨肉瘤中的预后价值。然后,为了进一步研究 SIRT1 在骨肉瘤中的作用,用小干扰 RNA SIRT1 处理骨肉瘤细胞,并过表达 SIRT1,以检测细胞迁移、侵袭和上皮-间充质转化(EMT)。骨肉瘤组织中 SIRT1 的表达水平明显高于相邻正常组织,SIRT1 蛋白水平可能与骨肉瘤患者的转移和预后不良风险相关。此外,SIRT1 沉默抑制骨肉瘤细胞在体外的迁移和侵袭能力,而 SIRT1 的过表达逆转了这些作用。最后,我们发现 SIRT1-ZEB1 正反馈增强了骨肉瘤的 EMT 过程和转移。总之,本研究结果表明,SIRT1 水平升高可能是骨肉瘤患者转移率高的生物标志物,提示抑制 SIRT1 可能是骨肉瘤治疗的一种有前途的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验